Our Tumor Immune Dysfunction and Exclusion analysis showed that ALDOA-high tumors exhibit higher immune exclusion scores, suggesting that patients with elevated ALDOA expression may be less responsive to immune checkpoint blockade therapy. The gene discussed is ALDOA; the disease is neoplasm.